Startups
Through innovative drug design, Xcovery has developed a comprehensive pipeline of oncology therapies with higher potency and low toxicity that target a wide range of advanced tumors. Xcovery is developing X-396, a small molecule that inhibits anaplastic lymphoma kinase (ALK), for treatment of ALK positive non-small cell lung cancer, lymphoma, and neuroblastoma. Xcovery is enrolling patients in the expansion cohort portion of a phase 1/2 study of X-396 for the treatment of non-small cell lung cancer where ALK is deregulated. The company also is preparing to initiate a phase 3 registration study in 2015.
Overview
Location
United States, Florida, North Palm Beach
Phone
+1 561-835-9356
Total raised
$20M
Founded date
2006
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 19, 2015 | Xcovery Presents at the 14th Annual BIO Investor Forum | -Company presents corporate update at investor forum – NEEDHAM, Mass. & PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–October 19, 2015– Xcovery, a developer of targeted therapeutics for cancer, today announced plans to present a company upda... |
| Oct 29, 2014 | Xcovery Raises $20M Equity Investment | Xcovery, a West Palm Beach, FL-based developer of targeted therapeutics for cancer, raised a $20m equity investment from Betta Pharmaceuticals Co., a Chinese pharmaceutical company focused on discovering, developing and delivering innovativ... |
| Oct 29, 2014 | Xcovery Raises $20M through Equity Investment from China's Betta Pharmaceuticals for Development of ALK Inhibitor | Betta Gains Chinese Rights to Phase 2 Asset, X-396 X-396 Phase 1 Data to be Presented at Multidisciplinary Symposium in Thoracic Oncology WEST PALM BEACH, Fla.–(BUSINESS WIRE)–October 29, 2014– Xcovery, a developer of next-generation target... |
| Oct 29, 2014 | Scripps cancer spinout Xcovery grabs $20M from a pharma partner in China | Chris Liang had already forged a compelling profile in drug development when the newly formed Scripps Florida recruited him as head of chemistry back in 2004. Liang, who emigrated from China in 1984 to attend grad school at Princeton, had w... |
| Jun 19, 2014 | Tyrogenex Receives $15M in Series D Financing | Tyrogenex Inc., a West Palm Beach, FL-based Xcovery Group company focused on discovering and developing novel patented cancer and ophthalmic therapeutics, received $15m in Series D financing. The backer was Brace Pharma, the U.S. investment... |
| Jun 19, 2014 | Tyrogenex Raises $15M in Series D | WEST PALM BEACH, FL, Xcovery Group company focused on discovering and developing novel patented cancer and ophthalmic therapeutics, has received $15 million in Series D financing. >> Click here for more funding data on Tyrogenex &... |
| Sep 19, 2012 | Xcovery Holdings Raises $6M in Series B | WEST PALM BEACH, FL, Parent company of Xcovery Vision, a privately held biopharmaceutical company, announced that it has raised a total of $6M in Series B financing from large family offices. >> Click here for more funding data on ... |
| Apr 16, 2012 | Lower toxicity cancer drug draws $1.6 million for TyroGeneX | A first in human clinical trial was initiated in February of last year in patients with advanced solid tumors. Targeted cancer therapeutics is expected to be a $51 billion playing field by 2015, led by Big Pharmas like Pfizer, Roche and Nov... |
| Lower toxicity cancer drug draws $1.6 million for TyroGeneX | A company developing a new generation of low-toxicity kinase inhibitors for treating cancer has raised almost half of the $3.5 million it’s targeting in the midst of a phase 1 clinical trial. TyroGeneX is developing a targeted small molecul... |
Show more
Reviews 0
FAQ about Xcovery
When was Xcovery founded?
Xcovery was founded in 2006.
How much funding has Xcovery raised?
Xcovery has raised $20M in total across 1 funding round.
What has the press written about Xcovery?
Parsers VC has collected 11 articles mentioning Xcovery, among them “Xcovery Presents at the 14th Annual BIO Investor Forum” (Oct 19, 2015) and “Xcovery Raises $20M Equity Investment” (Oct 29, 2014).
Is Xcovery still active?
Yes, Xcovery is active; its latest activity on Parsers VC dates from Jul 9, 2026.